We are live on ! Find out more
VCIM

Velan Capital Investment Management Portfolio holdings

AUM $160M
1-Year Est. Return 517.12%
This Fund
S&P 500
This Quarter Est. Return
+15.2%
1 Year Est. Return
+517.12%
3 Year Est. Return
+2,524.89%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$101M
AUM Growth
+$4.03M
Cap. Flow
-$1.4M
Cap. Flow %
-1.38%
Top 10 Hldgs %
69.32%
Holding
57
New
10
Increased
16
Reduced
5
Closed
7

Top Buys

Rank Stock Value
1
ALMS
Alumis Inc
ALMS
+$7.65M
2
ARVN icon
Arvinas
ARVN
+$3.68M
3
CDTX
Cidara Therapeutics
CDTX
+$2.4M
4
STRO icon
Sutro Biopharma
STRO
+$1.66M
5
TARA icon
Protara Therapeutics
TARA
+$1.63M

Top Sells

Rank Stock Value
1
SLRN
ACELYRIN
SLRN
+$8.32M
2
SWTX
SpringWorks Therapeutics
SWTX
+$8.19M
3
PRAX icon
Praxis Precision Medicines
PRAX
+$1.36M
4
TIL icon
Instil Bio
TIL
+$1.2M
5
IMNM icon
Immunome
IMNM
+$1.03M

Sector Composition

Rank Sector Weight
1 Healthcare 98.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HRTX icon
1
Heron Therapeutics
HRTX
$92.9M
$14.5M 14.29%
6,986,744
– –
VRNA
2
DELISTED
Verona Pharma
VRNA
$8.99M 8.88%
95,000
– –
JSPR icon
3
Jasper Therapeutics
JSPR
$23.6M
$7.96M 7.86%
1,433,828
– –
TARA icon
4
Protara Therapeutics
TARA
$232M
$6.48M 6.4%
2,139,000
+471,200
+28% +$1.63M
ZVRA icon
5
Zevra Therapeutics
ZVRA
$686M
$6.3M 6.22%
715,000
+50,000
+8% +$406K
TRML
6
DELISTED
Tourmaline Bio
TRML
$6.3M 6.22%
393,889
-61,523
-14% -$997K
PRAX icon
7
Praxis Precision Medicines
PRAX
$10.1B
$6.28M 6.2%
149,334
-35,666
-19% -$1.36M
CDTX
8
DELISTED
Cidara Therapeutics
CDTX
$4.87M 4.81%
+100,000
New +$2.4M
ALMS
9
Alumis Inc
ALMS
$3.52B
$4.86M 4.8%
+1,620,846
New +$7.65M
ARVN icon
10
Arvinas
ARVN
$572M
$3.68M 3.64%
+500,000
New +$3.68M
SCPH
11
DELISTED
scPharmaceuticals
SCPH
$3.5M 3.45%
917,668
– –
RZLT icon
12
Rezolute
RZLT
$452M
$3.35M 3.3%
750,000
+350,000
+88% +$1.3M
LQDA icon
13
Liquidia Corp
LQDA
$8.02B
$2.98M 2.94%
239,260
-60,740
-20% -$899K
MLYS icon
14
Mineralys Therapeutics
MLYS
$2.41B
$2.36M 2.33%
174,600
+24,000
+16% +$348K
STRO icon
15
Sutro Biopharma
STRO
$421M
$2.18M 2.16%
306,000
+203,000
+197% +$1.66M
NSPR icon
16
InspireMD
NSPR
$34.7M
$2.05M 2.03%
904,029
– –
CATX icon
17
Perspective Therapeutics
CATX
$342M
$1.72M 1.7%
500,000
– –
REPL icon
18
Replimune Group
REPL
$1.01B
$1.7M 1.68%
183,083
+1,000
+0.5% +$8.73K
TELA icon
19
TELA Bio
TELA
$38.9M
$1.45M 1.43%
747,410
– –
EDSA icon
20
Edesa Biotech
EDSA
$50.8M
$1.4M 1.38%
687,500
– –
NKTR icon
21
CALL
Nektar Therapeutics
NKTR
$2.58B
$1.29M 1.28%
+50,000
New +$561K
VRDN icon
22
Viridian Therapeutics
VRDN
$2.67B
$1.21M 1.19%
+86,500
New +$1.17M
UPB
23
Upstream Bio Inc
UPB
$395M
$1.17M 1.16%
107,000
– –
ELDN icon
24
Eledon Pharmaceuticals
ELDN
$285M
$919K 0.91%
338,973
+15,000
+5% +$45K
AVTX icon
25
Avalo Therapeutics
AVTX
$983M
$773K 0.76%
154,972
+43,000
+38% +$201K
1
2 3

Similar funds

BFAG
Blackston Financial Advisory Group The Villages, Florida $160M AUM 16.38% 1-Year Est. Return
SLG
Sanchez Levi Garrett $159M AUM
RFS
Richardson Financial Services Medway, Massachusetts $160M AUM 16.71% 1-Year Est. Return
SMF
Sterling Manor Financial Saratoga Springs, New York $160M AUM 13.84% 1-Year Est. Return
LCA
Legend Capital Advisors New York $160M AUM
SA
swisspartners Advisors Zurich, Switzerland $159M AUM 36.51% 1-Year Est. Return
SGCM
Sanchez Gaunt Capital Management Reno, Nevada $160M AUM
CF
CBM Financial Austin, Texas $160M AUM

Velan Capital Investment Management's Q2 2025 Portfolio in Review

As of Q2 2025, Velan Capital Investment Management held 57 positions worth $101M, up 4.1% from $97.2M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Velan Capital Investment Management's Q2 2025 filing shows 10 new, 16 increased, 5 reduced and 7 closed positions. Its largest new stake was Alumis Inc: 1,620,846 shares worth $4.86M. The largest sale was ACELYRIN, an estimated $8.32M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier.

  • Velan Capital Investment Management's largest Q2 2025 buy was Alumis Inc: 1,620,846 shares worth $4.86M.
  • Velan Capital Investment Management added most to Sutro Biopharma in Q2 2025, an estimated $1.66M increase.
  • Velan Capital Investment Management's biggest Q2 2025 reduction was Praxis Precision Medicines, cutting an estimated $1.36M.
  • Velan Capital Investment Management fully exited ACELYRIN in Q2 2025, selling an estimated $8.32M.
  • Velan Capital Investment Management's ten largest holdings make up 69% of its $101M portfolio in Q2 2025.
  • Velan Capital Investment Management opened 10 new positions and closed 7 in Q2 2025.
  • Velan Capital Investment Management's portfolio value rose 4.1% quarter-over-quarter to $101M.

Based on Velan Capital Investment Management's 13F filing for Q2 2025, filed 14 Aug 2025.